Abatacept approved by FDA for use in children


Bristol-Myers Squibb granted approval for arthritis biologic Orencia.

Children ages six years and older with moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) may now get some relief from using abatacept (

Related Videos
fake news misinformation | Image Credit: Bits and Splits - stock.adobe.com
Dr. Charles Lee
© 2024 MJH Life Sciences

All rights reserved.